Orgenesis Inc., (OTCQB:ORGS), a service and research company in the field of the regenerative medicine industry with a focus on cell therapy development and manufacturing for advanced medicinal products, today announced it has entered into an agreement with Adva Biotechnology Ltd., an innovator of enhanced bioprocessing solutions, for the development of an automated culturing system for use in the provision of contract manufacturing services, as well as Orgenesis’s therapeutic development. This system has the potential to enable cost-efficient and automated manufacturing for autologous cell therapies.
{iframe}https://stockguru.com/2018/02/06/orgenesis-and-adva-biotechnology-to-develop-and-distribute-advanced-automated-culturing-system-for-cell-therapy-manufacturing/{/iframe}